熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
PharmaMar PharmaMar
隸屬西班牙Zeltia生化科技集團(tuán)，20多年來致力于以海洋生物體研制新藥，
PharmaMar is a Spanish member of the Zeltia Group, a leader in the development of antitumor drugs of marine origin.
The oceans cover 70% of the Earth's surface, and correspond to 90% of the biosphere. For millions of years, innumerable forms of marine life have evolved to produce an immense variety of chemical entities of exclusive sophistication. Among these, there are molecules with potent biological activities, developed as a form of biochemical warfare to survive in an extremely competitive environment. PharmaMar has identified the antitumour potential of these molecules, and is actively developing them as innovative treatments for cancer.
One of the company's commitments is to develop drugs to treat rare ("orphan") diseases, i.e. those affecting under 5 out of every 100,000 people, according to the EU's definition. PharmaMar has a strong portfolio of marine origin compounds in development
We research to provide solutions that improve the quality of life of cancer patients and their families.
知識產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請聯(lián)系：400-006-7520 ，我們會在第一時間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號
